Menu Close

What is Grastofil?

What is Grastofil?

Grastofil is indicated for the treatment of persistent neutropenia (ANC less than or equal to 1.0 x 109/L) in patients with advanced HIV infection, in order to reduce the risk of bacterial infections when other options to manage neutropenia are inappropriate.

Is Grastofil the same as Neupogen?

Neupogen and Grastofil are not interchangeable products. As of the August 2017 formulary update, new prescriptions for filgrastim for ODB eligible patients will be dispensed Grastofil, unless it specifies Neupogen with the appropriate LU code. Prescribers should notify their patients of the switch.

Is neutropenia a symptom of cancer?

Neutropenia can happen to anyone. It sometimes results from an infection, but it is also often a result of treatment for cancer. It is estimated that 50 percent of the people who get chemotherapy will develop neutropenia.

Who makes Grastofil?

Authorisation details

Publication details
Marketing-authorisation holder Accord Healthcare, SLU
Revision 14
Date of issue of marketing authorisation valid throughout the European Union 17/10/2013
Contact address World Trade Center Moll de Barcelona, s/n Edifici Est, 6a planta 08039 Barcelona Spain

When should I take Grastofil?

Filgrastim is given by subcutaneous (under the skin) or intravenous (into a vein) injection once daily. For people who are being treated with chemotherapy, treatment should start no sooner than 24 hours after the chemotherapy has been given.

How do you administer Grastofil?

The recommended starting dose of Grastofil® in adult patients is 5 µg/kg/day, administered as a single daily injection by subcutaneous bolus injection, by short intravenous infusion (15 to 30 minutes), or by continuous subcutaneous or continuous intravenous infusion.

How long can you live with neutropenia?

Chronic neutropenia is defined as lasting more than 2 months. It may eventually go away, or remain as a life-long condition. Some people are born with it (congenital neutropenia), and others develop it as young children.

How do you fix neutropenia?

Approaches for treating neutropenia include:

  1. Antibiotics for fever.
  2. A treatment called granulocyte colony-stimulating factor (G-CSF).
  3. Changing medications, if possible, in cases of drug-induced neutropenia.
  4. Granulocyte (white blood cell) transfusion (very uncommon)

When should I take Lapelga?

It must be given at least 24 hours after your course of chemotherapy. There should be a 2-week period between your pegfilgrastim dose and your next chemotherapy. If you miss your pegfilgrastim dose, check with your doctor before taking the missed dose.

Does Grastofil cause fever?

Stop taking the medication and seek immediate medical attention if any of the following occur: signs of acute respiratory distress syndrome (e.g., fever, shortness of breath, cough, or lung congestion)

What is Lapelga?

Lapelga® is used to treat neutropenia (nu-tro-peen-ee-ah). Neutropenia is a condition where the body makes too few white blood cells and which may be caused by drugs used to treat cancer. Neutropenia is the most serious common side-effect of chemotherapy.

What is generic Grastofil used for?

Grastofil is a medicine that contains the active substance filgrastim. Grastofil is used to stimulate the production of white blood cells in the following situations:

Is generic Grastofil the same as neupogen?

Grastofil is a ‘biosimilar medicine’. This means that Grastofil is similar to a biological medicine (the ‘reference medicine’) that is already authorised in the European Union (EU) and that Grastofil and the reference medicine contain the same active substance. The reference medicine for Grastofil is Neupogen. How is Grastofil used?

How is Grastofil made?

The filgrastim in Grastofil is produced by a method known as ‘recombinant DNA technology’: it is made by bacteria into which a gene (DNA) has been introduced that makes them able to produce filgrastim. What benefits of Grastofil have been shown in studies?

Can Grastofil be authorised for use in the EU?

Therefore, the Agency’s view was that, as for Neupogen, the benefits of Grastofil are greater than its risks and it can be authorised for use in the EU. What measures are being taken to ensure the safe and effective use of Grastofil?

Posted in Other